NCT01815866

Brief Summary

Non-tuberculous mycobacteria (NTM) are opportunistic pathogens normally found in soil and water that are being cultured from Cystic Fibrosis (CF) airways at an increasing frequency. They have been demonstrated to cause clinically significant lung disease in some cases and the transmission of NTM, from person to person has been proposed. There are currently no standardized guidelines for isolation of those colonized or infected with NTM. The investigators will measure particle droplet size from patients with CF who have positive sputum cultures for NTM with the hypothesis that they will be in a range that can spread infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 19, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 21, 2013

Completed
11 days until next milestone

Study Start

First participant enrolled

April 1, 2013

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
Last Updated

October 14, 2015

Status Verified

October 1, 2015

Enrollment Period

2.2 years

First QC Date

March 19, 2013

Last Update Submit

October 13, 2015

Conditions

Keywords

Positive Nontuberculous Mycobacteria

Outcome Measures

Primary Outcomes (1)

  • The number of CF patients who produce culturable aerosols of NTM during coughing.

    Patients with CF and a positive sputum or bronchoalveolar lavage (BAL) culture for NTM will cough into a chamber filled with culture plates that can measure droplet size. The investigators are looking for large droplets, that could land on surfaces and be a source for infection transmission, as well as fine droplets(5 microns or less)that are consistent with airborne transmission.

    6 weeks

Study Arms (1)

CF with culturable NTM

CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.

Procedure: CF with culturable NTM

Interventions

CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.

CF with culturable NTM

Eligibility Criteria

Age8 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Specialialty Clinics, Pulmonary

You may qualify if:

  • Age greater than or equal to age 8 years
  • Confirmed Diagnosis of CF
  • Sputum/Throat/Bronchoscopic culture positive for NTM within the last 12 months

You may not qualify if:

  • Pregnancy
  • Pneumothorax within the last 6 months
  • Forced Expiratory Volume at one second \<30% predicted
  • Hemoptysis greater than 1 tablespoon within the last 7 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Florida Clinical Research Center

Gainesville, Florida, 32610, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Sputum cultures

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Study Officials

  • Pamela M Schuler, MD

    University of Florida

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2013

First Posted

March 21, 2013

Study Start

April 1, 2013

Primary Completion

July 1, 2015

Study Completion

July 1, 2015

Last Updated

October 14, 2015

Record last verified: 2015-10

Locations